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Abstract  We investigated the impact of multidrug therapy (MDT) on the epidemiological pat-
tern of leprosy in Juiz de Fora, Brazil, from 1978 to 1995. Evaluation of 1,283 medical charts was
performed according to the treatment regimen used in two different periods. Following the intro-
duction of MDT in 1987, prevalence of leprosy decreased from 22 patients/10,000 inhabitants to
5.2 patients/10,000 inhabitants in 1995. Incidence rate of leprosy was lower in period II (1987-
1995) than in period I (1978-1986). Decreasing prevalence and incidence appear to be related to
drug efficacy rather than decreased case identification, since both self-referred and professional-
ly referred treatment increased markedly from period I to period II. For both periods, multibacil-
lary leprosy was the most frequent clinical form of the disease (±68%), and the main infection
risk factor identified was household contact. Leprosy is predominantly manifested in adults, but
an increase in the number of very old and very young patients was observed in period II. The
MDT program has been effective both in combating leprosy and in promoting awareness of the
disease.
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Resumo  Investigamos o impacto da poliquimioterapia (PQT) no perfil epidemiológico da
hanseníase em Juiz de Fora, Brasil, de 1978 a 1995. Fizemos uma avaliação de 1.283 prontuários,
de acordo com o esquema terapêutico adotado em dois diferentes períodos. Desde a introdução
da PQT, em 1987, a prevalência da hanseníase caiu de 22 pacientes/dez mil habitantes para 5,2
pacientes/dez mil habitantes em 1995. A incidência da doença foi menor no período II (1987-
1995) em comparação ao período I (1978-1986). A diminuição da prevalência e da incidência es-
tá mais relacionada à eficácia das drogas que a uma queda na identificação da infecção, já que
tanto a procura espontânea quanto os encaminhamentos aumentaram significativamente do
período I para o período II. Em ambos os períodos, a forma clínica mais freqüente foi a multi-
bacilar (±68%), e o contato intradomicilicar foi o maior fator de risco conhecido associado à in-
fecção. Um aumento de pacientes muito velhos ou muito novos foi observado no período II. Os
resultados indicam que o esquema PQT tem sido eficaz no combate à hanseníase e tem aumen-
tado a conscientização e o conhecimento da doença.
Palavras-chave  Hanseníase; Quimioterapia Combinada; Prevalência; Epidemiologia
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Introduction
Leprosy is a chronic infectious disease that
represents a major public health problem, af-
fecting some 1.8 million people worldwide
(WHO, 1994). An estimated 2 to 3 million indi-
viduals suffer from physical disabilities as a re-
sult of having contracted leprosy (Van Beers et
al., 1994). Although it is one of the oldest dis-
eases afflicting humans, the possibility of treat-
ment and cure did not come until the advent of
sulfones in the 1940s. However, the results of
sulfone use proved unsatisfactory. Dapsone
failed to prevent the growth of resistant bacil-
lus (Dharmendra, 1986), and new potent drugs
like clofazimine (Browne & Hogerzeil, 1962) and
rifampicin (Opromolla et al. 1965; Levy et al.,
1976) were unable to prevent spread of the dis-
ease when used as monotherapeutic agents. In
1981, the World Health Organization (WHO) be-
gan to recommend a multidrug therapy (MDT)
of dapsone, clofazimine, and rifampicin. MDT
was an effective strategy and allowed for reduced
treatment times compared to monotherapy:
from five to two years for the lepromatous (L) or
dimorphous (D) multibacillary forms (MB) and
from 2 years to 6 months for the tuberculoid (T)
or indeterminate (I) paucibacillary forms (PB).
MDT was introduced into Brazil in 1986 and
was authorized for leprosy treatment in 1992. 
Based on the efficacy of MDT for leprosy,
WHO has targeted elimination of the disease as
a worldwide public health problem by the year
2000. To do so, it has enrolled authorities from
countries with high rates of the disease. Brazil
currently has the second highest prevalence and
incidence of leprosy in the world. The Brazilian
government, through its State Health Depart-
ments, has been working to reduce prevalence
of the disease to less than 1 case per 10,000 in-
habitants, considered a low rate by WHO.
Juiz de Fora, a city with 414,520 inhabitants
(population estimate for 1995), has many lep-
rosy patients, but the disease’s epidemiological
pattern here has not been described to date.
This article analyzes the main characteristics
of leprosy in Juiz de Fora and investigates the
impact of MDT on the disease’s epidemiologi-
cal pattern.
Patients and methods
Juiz de Fora is the home of a regional health of-
fice for the State of Minas Gerais and serves a
large number of nearby cities by providing
drugs and human resources for leprosy treat-
ment and control. The city has two health cen-
ters providing care for people with leprosy: the
“Dr. Antônio Carlos Pereira Filho” Dermatology
Sector and the University Hospital. We studied
the epidemiological patterns of leprosy pa-
tients over two defined periods, differing in
their use of MDT and in some characteristics of
the control program, as described in Table 1.
In the first phase of the study, the medical
charts of 1,283 patients were analyzed to deter-
mine annual incidence and prevalence of the
disease. Patients were treated at leprosy health
centers in Juiz de Fora. The 1,283 patients in-
cluded 375 cases reported prior to 1978, 534
new cases reported during period I (1978-
1986), and 374 new cases reported during peri-
od II (1987-1995). Less than 10% of the patients
from period I were treated with MDT, and some
90% had sulfone monotherapy from the Na-
tional Sanitary Dermatology Division (DNDS).
In contrast, approximately 90% of the patients
from period II were treated with MDT, and less
than 10% with the DNDS regimen. Leprosy
classification was based on clinical presenta-
tion, bacilloscopy, Mitsuda test, and classic
histopathology (MS, 1989) in both periods. Mit-
suda test was used mainly to assist definition
of indeterminate forms of leprosy. Until 1993,
patients were considered cured after comple-
tion of treatment if clinical signs and bacil-
loscopy were both negative; otherwise they re-
mained under observation for an additional
period of 5 years (MB) or 2 years (PB). Statisti-
cal criteria for discharge were adopted in 1987.
Patients absent from health units for a period of
a year or more whose treatment was not com-
pleted were considered non-compliant and dis-
charged by statistical criteria after completing 2
years (PB) or 5 years (MB) of dropout. Fixed-
duration treatment was introduced in 1993.
Treatment efficacy was evaluated by the
number of discharges resulting from cure and
by comparing prevalence and incidence rates
for the two study periods. In the second phase
of the analysis, the case identification strategy,
most frequent clinical presentation, age distrib-
ution, and source of infection were determined
by analysis of randomly sampled medical
charts. 314 files were selected in each of the two
study periods, totaling 628 new case protocols.
Data were analyzed using EPI Info 6.03. We
first did a descriptive statistical analysis for the
two groups enrolled in this study. The results of
phase one (Table 2) were compared by analysis
of variance of the means using the non-para-
metric Kruskal-Wallis method. For the results
in phase two (Figures 1-3), chi-squared statis-
tics were used to analyze the data. The signifi-
cance level was 5%. 
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Table 1
Characteristics of Period I and Period II.
Period I Period II
Time period 01/01/78 to 12/31/86 01/01/87 to 12/31/95
Main drugs and length DNDS MDT
of treatment MB: Rfm + Dds (first 3 months) and Dds alone MB: Rfm + Dds + Cfz (normally 24 months, 
(through the remainder of 5 years) up to 36 months)
PB: Dds (2 years) PB: Rfm + Dds (normally 6 months, up to 9 months)
Discharge based Not performed Performed 
on statistical criteria
Examination of contacts Less frequent More frequent
BCG vaccinationa Less frequent More frequent
Professional training Less frequent More frequent
a BCG was introduced in 1989 for all MB contacts and in 1993 for all leprosy contacts. 
Before 1989 it was only used for scar-negative contacts (usually children from 0 to 4 years of age). 
Rfm = Rifampin; Dds = Dapsone; Cfz = Clofazimine; MB = Multibacillary Forms; PB = Paucibacillary Forms; 
DNDS = National Sanitary Dermatology Division; MDT = Multidrug Therapy
Table 2
Number of admissions and discharges from leprosy register in Juiz de Fora in two periods.
Year Casesa Admissionsb Dischargesc Populationd Incidence/ Prevalence/
Cure Death Change Stat. Total 100,000 10,000
of resid. Criteria inhab. inhab.
1978 375 49 0 0 0 0 0 293,000 17 14
1979 424 91 0 0 0 0 0 300,000 30 17
1980 515 66 1 0 2 0 3 307,525 21 19
1981 578 36 4 0 4 0 8 314,658 11 19
1982 606 45 20 1 3 0 24 321,789 14 19
1983 627 60 13 0 2 0 15 328,920 18 20
1984 672 95 4 0 10 0 14 336,051 28 22
1985 753 50 6 3 7 0 16 343,182 14 23
1986 787 42 1 4 14 0 19 350,313 12 22
Total 534 49 8 42 0 99
1987 810 32 76 5 28 34 143 357,444 9 19
1988 699 47 75 9 15 7 96 364,575 13 17
1989 640 33 68 9 4 14 95 371,706 9 15
1990 578 55 77 4 7 29 117 378,834 14 14
1991 516 39 45 2 8 22 77 385,996 10 12
1992 478 53 61 7 6 42 116 393,127 13 10
1993 415 37 94 2 11 29 136 400,258 9 8
1994 316 55 82 2 4 19 107 407,389 13 6
1995 264 23 34 1 9 28 72 414,520 5 5
Total 374 612 41 92 224 959
a – number of leprosy cases in active file at the end of previous year. 
b – number of new cases recorded.
c – number of cases excluded  from active file due to cure, death, change of residence, or statistical criteria. 
d – estimated population for the year.
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Results
The impact of MDT on the number 
of leprosy patients in Juiz de Fora
MDT was introduced in Juiz de Fora in 1987
and caused a reduction in treatment time. This
change coincided with improvements in the
leprosy surveillance system, including more
frequent examination of contacts and profes-
sional training. In addition, a statistical criteri-
on was introduced for patient removal from the
register due to treatment non-compliance, and
BCG vaccination was adopted in 1989 in an at-
tempt to stimulate protective anti-mycobacte-
rial responses in leprosy contacts (Table 1). 
From 1978 to 1986 (period I), the number of
new cases recorded in Juiz de Fora exceeded
the number of discharges of patients on active
file from the city health units, such that the to-
tal number of registered cases increased every
year, peaking at 787 in 1986 (Table 2). Disease
prevalence increased from 14.4 patients/10,000
inhabitants in 1978 to 22 patients/10,000 in-
habitants in 1986. During this time, 534 new in-
dividuals were added to the register and only
99 were removed. Reasons for removal from the
register were as follows: cure, 49.5%; change of
residence, 42.4%, and death, 8%. In contrast,
from 1987 to 1995 (period II), discharges (re-
moval from the register) outnumbered new
cases. There were a total of 810 cases in 1987,
but the figure dropped to 264 by 1995. Accord-
ingly, during period II, 959 discharges oc-
curred. This was almost 10 times the figure for
period I. A total of 63.8% of the patients were
discharged due to cure, 23.3% based on statis-
tical criteria, 9.6% because of change of resi-
dence, 4.3% due to death. The results suggest
that the use of MDT improved the epidemio-
logical control of the disease, reversing the flow
of new cases and discharges, demonstrating a
statistically significant improvement in the
number of discharges due to cure (p = 0.0003),
and reducing the overall disease prevalence
from 19.5 cases/10,000 inhabitants in 1987 to
5.2 cases/10,000 inhabitants in 1995. Table 2 al-
so shows that while the leprosy incidence rate
in Juiz de Fora varied, it was lower during peri-
od II as compared to period I (p = 0.0051), sug-
gesting that the incidence decreased after intro-
duction of MDT, perhaps as a result of the de-
creased number of individuals infecting others.
Comparison of new case detection 
in period I vs. period II
Figure 1 shows the frequency of ways by which
new leprosy cases were detected in Juiz de Fora
in the two treatment periods. Patient self-refer-
ral for treatment at health units was the most
frequent method of new case identification in
period II (48.4%). This was clearly higher than
patient self-referral during period I (11.1%).
Likewise, the percentage of patients identified
by health care professionals increased from
2.2% during period I to 26.8% during period II.
Case identification through tests of previously
identified patient contacts also became more
prevalent in Juiz de Fora in period II (10.2%) as
compared to period I (3.5%). In contrast, there
was a reduction in the percentage of cases
identified by mass screening (3.2% to 1.3%) as
well as a reduction in the percentage of pa-
tients whose case identification mechanism
was not determined during period II (13.4%) as
compared to period I (79.9%). The overall dis-
tribution of case identification changed in a
statistically significant manner (χ2 = 300.27, 4
df, p<0.0001) between the two periods. 
Multibacillary forms of leprosy predominate 
over paucibacillary forms
It is well known that leprosy manifests as a
spectrum of different clinical presentations. In
our study, we observed that the multibacillary
forms (lepromatous and dimorphous) pre-
dominated over paucibacillary forms (tubercu-
loid and indeterminate) in both study periods
(Figure 2). A reduction in the percentage of all
leprosy cases with the lepromatous clinical
form (60.8% to 33.8%) from period I to period
II was accompanied by an increase in dimor-
phous cases (1.9% to 38.5%). In contrast, the
percentage of patients with tuberculoid leprosy
did not show a significant variation, remaining
at ≅19.5%. Patients with indeterminate leprosy
represent less than 15% of the total number of
patients, showing a drop from 14% to 11.8%
from the first to second period. The overall dis-
tribution showed a statistically significant
change from period I to period II (χ2 = 133.37, 3
df, p<0.0001). 
The increased incidence of leprosy 
at extreme ages
Figure 3 shows that although leprosy was diag-
nosed mainly between 15 and 59 years of age,
the percentage of patients 60 and over in-
creased (from 7.5% to 12.5%) as did the per-
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Figure 1
Leprosy case identification strategy in Juiz de Fora in the two periods.
Figure 2
Clinical distribution of leprosy in the two periods.
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centage of clinical presentations in patients
below 15 years of age (1.0% to 4.6%). The
overall change was significant (χ2 = 12.52, 5 df,
p = 0.0283). 
Discussion
The epidemiological features of leprosy were
analyzed in Juiz de Fora, Brazil, focusing on the
introduction of the MDT protocol and its im-
pact on the epidemiological control of the dis-
ease. Our results demonstrate that use of MDT
in Juiz de Fora beginning in 1986 caused a
sharp decrease in overall disease prevalence as
well as a significant increase in the number of
discharges resulting from leprosy cure. These
data suggest the efficacy of the MDT regimen
for treatment of leprosy and confirm the preva-
lence studies described in other regions of
Brazil (Nogueira et al., 1995; MS, 1998). Accord-
ingly, recent data indicate that prevalence rates
for leprosy in Juiz de Fora have continued to
drop, with only 1.8 patients/10,000 inhabitants
in 1996 and 1.6 patients/10,000 inhabitants in
1997 and 1998 (A. F. M. Pimentel, personal com-
munication). This appears to be a continuation
of the decreased incidence reported in this
study between periods I and II. However, these
findings are in contrast with the increased de-
tection rates for new leprosy cases observed
throughout Brazil during the period from 1986
to 1997 (MS, 1998). This disparity could be ex-
plained by large differences between leprosy
incidence in different regions of Brazil as well
as differential employment of MDT regimens.
However, our data are consistent with the re-
sults described by others using retrospective
analysis of data on the occurrence of leprosy
worldwide (Myint & Htoon, 1996; Meima et al.,
1997). 
We are aware that the reduction in treat-
ment time and implementation of statistical
criteria for being discharged from the active
file (both adopted after 1986) may have some
influence on the interpretation of the success
of MDT. Increased BCG vaccine coverage could
also have affected our data by lowering the in-
cidence of the lepromatous form, since it has
been demonstrated that BCG confers protec-
tion against leprosy and is able to decrease the
proportion of MB forms (Rodrigues et al., 1992;
Bertolli et al., 1997). Still, we believe that im-
plementation of the MDT program in Juiz de
Fora has produced major changes in patient
treatment and cure. Since these changes were
accompanied by improvements in both sur-
veillance and health services’ availability and
quality, it is highly unlikely that the decrease in
incidence and prevalence are merely the result
of changes in the definition of cure or vaccine
coverage.
The increase in frequency of patient self-re-
ferral for treatment of leprosy at health units in
Juiz de Fora suggests that after the initiation of
the MDT program there was an improvement
Figure 3
Age distribution of leprosy in the two periods.
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in the population’s knowledge of the early signs
and symptoms of the disease and the avail-
ability of medical care. In addition, improved
recognition of the disease by health profes-
sionals and increased surveillance of patient
contacts resulted in a higher percentage of case
identification through referral by health pro-
fessionals. The reduction in the percentage of
patients identified by mass screening confirms
other studies, according to which this high-
cost strategy for detecting new cases has been
discontinued (Theuvenet et al., 1994). 
As expected, the percentage of patients
who acquired the disease through household
contacts (≅24%) was higher than for those who
acquired the disease by other known sources
(≅7%) in both periods. The majority of patients
(≅68% in both periods) could not identify the
source of infection. The close association of the
patients with asymptomatic leprosy carriers
living in endemic areas of disease may explain
the occurrence of new cases of leprosy for
which the source of infection is not known (Van
Beers et al., 1994). This possibility is enhanced
by the long viability of Mycobacterium leprae
outside the human body (Desikan & Sreevatsa,
1995). These data implicate a role of genetic
features and prolonged contact with asympto-
matic carriers in the spread of disease (Kyriakis
et al., 1994; Mehra et al., 1995; Abel et al., 1998).
However, there is still little information on the
main source of infection in these situations.
The multibacillary forms of leprosy pre-
dominated during both periods, but the fre-
quency of dimorphous and lepromatous forms
differed. Such variation may be explained by
changes in the evaluation criteria for clinical
presentations and by improved diagnostic ac-
curacy. However, most dimorphous cases in
period II are, in fact, skin-smear-negative pa-
tients (83.6%), as compared to the smear-posi-
tive patients who were predominant among
the lepromatous patients in period II (73.6%),
showing a highly significant difference (χ2 =
61.18, 1 df, p<0.0001). Hence, we cannot ex-
clude the possibility that the described shift in
dimorphous frequency and the high detection
rate for MB leprosy may, to a certain degree, re-
flect a conservative behavior in which clini-
cians prefer to choose longer treatment for lep-
rosy patients (Martelli et al., 1995). The inci-
dence of leprosy in females (44.5%) was lower
than in males (55.5%), but the difference was
not statistically significant (χ2 = 1.17, df = 1, p =
0.2783); interestingly, a higher percentage of
MB leprosy was observed in males than fe-
males (73.7% versus 59.6%) during both peri-
ods (χ2 = 13.99, 1 df, p<0.0002). These findings
reinforce the concept that immune responses
against M. leprae are stronger in females than
in males (Olrich et al., 1993).
Although most leprosy cases occur between
15 and 60 years of age, the current data suggest
a broader age distribution in this population.
An increased frequency of leprosy in patients
60 years of age or older was observed, similar
to reports by others (Smith & Richardus, 1993).
The percentage of children under 15 with the
disease changed from low to moderate accord-
ing to WHO criteria. The same results were also
described elsewhere (MS, 1998) and are con-
sidered an indicator of a higher rate of disease
occurrence, but they may also be associated in
some way with improvements in case detec-
tion. 
During period II, 224 patients were dis-
charged by statistical criteria and were thus
lost to follow-up along with 284 asymptomatic
leprosy carriers who have a significant risk of
developing the disease in the future. Neverthe-
less, the use of MDT as a new treatment proto-
col for leprosy patients reduced the non-com-
pliance rate in Juiz de Fora from 90% in 1986 to
56% in 1995. This non-compliance rate is still
considered high and might jeopardize the lep-
rosy control program, since the lack of com-
pleted patient treatment and contact follow-up
could lead to development of resistant bacilli. 
The MDT program shows good prospects
for the cure of leprosy and its elimination as a
public health problem (WHO, 1994). However,
we must not forget that the control and eradi-
cation of the disease hinge on different collec-
tive efforts that can interfere with the spread
and evolution of the disease. Such efforts are
not restricted to the use of drugs against M.
leprae but can also employ integrated nutri-
tional programs, BCG coverage, school curric-
ula, and sanitary conditions. These factors may
also influence the efficacy of patients’ immune
response, clinical presentation, and treatment
results.
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